Carmell Therapeutics

Biotechnology

Carmell is a biotechnology company focused on the development and commercialization of regenerative medicine technologies. Founded as a spin-out of Carnegie Mellon University in Pittsburgh, PA, Carmell Therapeutics has created a unique and highly innovative patented technology based on biologically-active materials manufactured from human blood plasma. These Plasma-based Bioactive Materials (PBMs) contain a concentration of natural regenerative factors that promote healing in various clinical settings, reduce infections, reduce complications, and, as a result, save healthcare costs. 

Cantilever holds convertible debt in this company.

www.carmellrx.com